A randomized, placebo-controlled phase I trial of DNA prime, recombinant fowlpox virus boost prophylactic vaccine for HIV-1

Anthony D. Kelleher, Rebekah L. Puls, Mark Bebbington, David Boyle, Rosemary Ffrench, Stephen J. Kent, Sue Kippax, Damian F.J. Purcell, Scott Thomson, Handan Wand, David A. Cooper, Sean Emery

Research output: Contribution to journalArticleResearchpeer-review

54 Citations (Scopus)

Abstract

An HIV-vaccine consisting of a DNA prime, recombinant fowlpox virus (rFPV) boost was evaluated in a double-blind placebo controlled trial. One milligram of pHIS-HIV-B expressing mutated gag, pol, env, vpu, tat and rev was administered at weeks 0 and 4 boosted by 5 × 107 pfu rFPV-HIV-B expressing gag/pol at week 8. The vaccine regimen was safe, but there was no difference between vaccine (n = 18) and placebo recipients (n = 6) for Gag or Pol-specific T-cell immune responses at week 9.

Original languageEnglish
Pages (from-to)294-297
Number of pages4
JournalAIDS
Volume20
Issue number2
DOIs
Publication statusPublished - 1 Jan 2006

Cite this

Kelleher, Anthony D. ; Puls, Rebekah L. ; Bebbington, Mark ; Boyle, David ; Ffrench, Rosemary ; Kent, Stephen J. ; Kippax, Sue ; Purcell, Damian F.J. ; Thomson, Scott ; Wand, Handan ; Cooper, David A. ; Emery, Sean. / A randomized, placebo-controlled phase I trial of DNA prime, recombinant fowlpox virus boost prophylactic vaccine for HIV-1. In: AIDS. 2006 ; Vol. 20, No. 2. pp. 294-297.
@article{0777248c5636487197425faa00f9614a,
title = "A randomized, placebo-controlled phase I trial of DNA prime, recombinant fowlpox virus boost prophylactic vaccine for HIV-1",
abstract = "An HIV-vaccine consisting of a DNA prime, recombinant fowlpox virus (rFPV) boost was evaluated in a double-blind placebo controlled trial. One milligram of pHIS-HIV-B expressing mutated gag, pol, env, vpu, tat and rev was administered at weeks 0 and 4 boosted by 5 × 107 pfu rFPV-HIV-B expressing gag/pol at week 8. The vaccine regimen was safe, but there was no difference between vaccine (n = 18) and placebo recipients (n = 6) for Gag or Pol-specific T-cell immune responses at week 9.",
author = "Kelleher, {Anthony D.} and Puls, {Rebekah L.} and Mark Bebbington and David Boyle and Rosemary Ffrench and Kent, {Stephen J.} and Sue Kippax and Purcell, {Damian F.J.} and Scott Thomson and Handan Wand and Cooper, {David A.} and Sean Emery",
year = "2006",
month = "1",
day = "1",
doi = "10.1097/01.aids.0000199819.40079.e9",
language = "English",
volume = "20",
pages = "294--297",
journal = "AIDS",
issn = "0269-9370",
publisher = "Lippincott Williams & Wilkins",
number = "2",

}

Kelleher, AD, Puls, RL, Bebbington, M, Boyle, D, Ffrench, R, Kent, SJ, Kippax, S, Purcell, DFJ, Thomson, S, Wand, H, Cooper, DA & Emery, S 2006, 'A randomized, placebo-controlled phase I trial of DNA prime, recombinant fowlpox virus boost prophylactic vaccine for HIV-1', AIDS, vol. 20, no. 2, pp. 294-297. https://doi.org/10.1097/01.aids.0000199819.40079.e9

A randomized, placebo-controlled phase I trial of DNA prime, recombinant fowlpox virus boost prophylactic vaccine for HIV-1. / Kelleher, Anthony D.; Puls, Rebekah L.; Bebbington, Mark; Boyle, David; Ffrench, Rosemary; Kent, Stephen J.; Kippax, Sue; Purcell, Damian F.J.; Thomson, Scott; Wand, Handan; Cooper, David A.; Emery, Sean.

In: AIDS, Vol. 20, No. 2, 01.01.2006, p. 294-297.

Research output: Contribution to journalArticleResearchpeer-review

TY - JOUR

T1 - A randomized, placebo-controlled phase I trial of DNA prime, recombinant fowlpox virus boost prophylactic vaccine for HIV-1

AU - Kelleher, Anthony D.

AU - Puls, Rebekah L.

AU - Bebbington, Mark

AU - Boyle, David

AU - Ffrench, Rosemary

AU - Kent, Stephen J.

AU - Kippax, Sue

AU - Purcell, Damian F.J.

AU - Thomson, Scott

AU - Wand, Handan

AU - Cooper, David A.

AU - Emery, Sean

PY - 2006/1/1

Y1 - 2006/1/1

N2 - An HIV-vaccine consisting of a DNA prime, recombinant fowlpox virus (rFPV) boost was evaluated in a double-blind placebo controlled trial. One milligram of pHIS-HIV-B expressing mutated gag, pol, env, vpu, tat and rev was administered at weeks 0 and 4 boosted by 5 × 107 pfu rFPV-HIV-B expressing gag/pol at week 8. The vaccine regimen was safe, but there was no difference between vaccine (n = 18) and placebo recipients (n = 6) for Gag or Pol-specific T-cell immune responses at week 9.

AB - An HIV-vaccine consisting of a DNA prime, recombinant fowlpox virus (rFPV) boost was evaluated in a double-blind placebo controlled trial. One milligram of pHIS-HIV-B expressing mutated gag, pol, env, vpu, tat and rev was administered at weeks 0 and 4 boosted by 5 × 107 pfu rFPV-HIV-B expressing gag/pol at week 8. The vaccine regimen was safe, but there was no difference between vaccine (n = 18) and placebo recipients (n = 6) for Gag or Pol-specific T-cell immune responses at week 9.

UR - http://www.scopus.com/inward/record.url?scp=33646045350&partnerID=8YFLogxK

U2 - 10.1097/01.aids.0000199819.40079.e9

DO - 10.1097/01.aids.0000199819.40079.e9

M3 - Article

C2 - 16511428

AN - SCOPUS:33646045350

VL - 20

SP - 294

EP - 297

JO - AIDS

JF - AIDS

SN - 0269-9370

IS - 2

ER -